Tongue cancer, oral cancer Tongue cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Healthy volunteers: In order to be eligible to participate in this study, healthy volunteers will participate who are able to understand the research requirements and who will sign an informed consent form. The age of volunteers is between 18-80 years old at the time of signing the informed consent. To participate in this study, subjects must be able to read, speak and understand the Dutch language. Patients: In order to be eligible to participate in this study, a patient must meet all following criteria: patients over 18 years of age with newly diagnosed T1-T2 N0 squamous cell carcinoma of the tongue that will be planned for curative therapy, a partial glossectomy with primary closure or free flap reconstruction. To participate in this study subjects must be able to read, speak and understand the Dutch language, the participant information and the informed consent.
Exclusion criteria
Exclusion criteria: Healthy volunteers: Exclusion criteria are metal braces, dental splints, or any general MRI contraindication. Patients: A potential patient who meets any of the following criteria will be excluded from participation in this study: - Postoperative radiation therapy - ASA IV or V - Absolute contraindications for MRI (e.g. pacemaker, ICD or surgery in the last 6 months) - Orthodontic braces - Pregnancy or potential pregnancy - Claustrophobic or anxious during MRI - Orthopnea - Unable to lie down and lie still for 30 minutes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In the first part of the study the main study parameter is the feasibility and repeatability of an advanced 3D-dMRI to depict speech and swallowing. In the second part of the study the main endpoint is the feasibility of 3D-dMRI, manofluorography, and OPG to detect differences in speech and swallowing function before and after surgery of tongue cancer. | — |
Countries
Netherlands
Contacts
Antoni van Leeuwenhoek (AVL)